ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1125

Adult Outcome of Childhood-Onset Steroid-Dependent Idiopathic Nephrotic Syndrome in the Rituximab Era

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Plaisier, Emmanuelle M., APHP Tenon, Paris, France
  • Dossier, Claire, APHP Robert Debré, Paris, France
  • Dahan, Karine, APHP Tenon, Paris, France
  • Ronco, Pierre M., APHP Tenon, Paris, France
  • Baudouin, Veronique, APHP-Robert Debré Hospital, Paris, France
  • Ulinski, Tim, APHP - Trousseau and UPMC, Paris, France
  • Deschênes, Georges, APHP Robert Debré, Paris, France

Idiopathic nephrotic syndrome (INS) represents the most frequent glomerular disease in childhood, with up to 60% of patients experiencing frequent relapses and steroid dependency requiring long-lasting steroid therapy and immunosuppressive (IS) drugs. Outcome and optimal therapy at adulthood, as well as long-term complications of childhood IS exposure is poorly documented.


We retrospectively analyzed a monocentric cohort of 43 patients with childhood-onset steroid-dependent INS. Relapses in adulthood were treated with steroids or a combinaison of steroids and rituximab (RTX), with the exclusion of all other IS .


Median age at the INS diagnosis and at the last follow-up was 4 years (1-17) and 24 (19-40) years, respectively, with a median duration of follow-up at adulthood of 7 (1-21) years. At pediatric age, 42 (98%) patients received at least one nonsteroidal IS drug, including calcineurin inhibitors in 29 (67%), mycophenolate mofetil in 26 (60%), RTX in 17 (39%), an alkylating agent in 15 (35%), and levamisole in 13 (30%). At entry in the adult care, 16 (37%) of the patients still received an IS drug other than RTX. Relapse occurred in 32 (74%) of patients at adult age with 5 patients presenting at least 2 episodes. In 9 patients, relapse occurred more than 3 years after steroids and IS discontinuation. Relapses were treated with steroids alone in two patients, while the other 29 received a combination of steroids and RTX, followed, for 20/29 patients, by a reinfusion of RTX either at B-cell recovery or at fixed intervals (6 to 12 months), up to 24 months. At last follow-up, 36 (84%) patients were in complete remission, with a treatment-free duration of more than 24 months in 12 (28%), of 12 to 24 months in 8 (19%) and of less than 12 months in 16 (37%). All but one patients were free of steroids and IS drugs. No patient experienced infection or cytopenia and one patient developed neoplasia most likely unrelated to IS.


Childhood-onset steroid-dependent INS remains a concern at adulthood with a high rate of relapse occurring after a variable delay. RTX is a safe and efficient steroid-sparing agent allowing maintenance of remission and discontinuation other IS. No late-onset severe complication related to childhood therapies was recorded.